- NCIt
- C6959
Loading cancer entity…
Loading cancer entity…
Clinical trials
38 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (6)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05600491 | A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme | unknown | Phase 3 | 78 | Sun Yat-sen UniversityOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT01765088 | A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas | unknown | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT02629757 | A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas(β-elemene) | unknown | Phase 3 | 100 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT02795364 | Study About the Validity of MRS-guided Resection on Prognosis High-grade Glioma Gliomas | unknown | N/A | 50 | Huashan HospitalOTHER | 0 | Jun 10, 2016 | clinicaltrials |
| NCT01656980 | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | unknown | Phase 3 | 236 | Shandong Lanjin Pharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 3, 2012 | clinicaltrials |
| NCT01637753 | Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma | unknown | N/A | 212 | Shandong Lanjin Pharmaceuticals Co.,LtdINDUSTRY | 1 | Jul 11, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Oct 31, 2022source: clinicaltrials